There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aldeyra Therapeutics (ALDX) and Blueprint Medicines (BPMC) with bullish sentiments.
Aldeyra Therapeutics (ALDX)
In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Aldeyra Therapeutics, with a price target of $35. The company’s shares opened today at $7.76, close to its 52-week low of $6.75.
Piros commented:
“: We reiterate our OW rating and 12-month $35 PT on ALDX following 1Q19 earnings. Aldeyra is making monumental progress across its late stage programs. We believe Aldeyra is underappreciated, given the company has late stage programs that target large market opportunities. Aldeyra has already established proof of concept in numerous late stage programs. In light of the recent Xiidra acquisition, we believe Aldeyra’s dry eye disease program could become of interest to other ophthalmology-focused companies.”
According to TipRanks.com, Piros is a 1-star analyst with an average return of -0.8% and a 45.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Aldeyra Therapeutics is a Moderate Buy with an average price target of $31.50.
See today’s analyst top recommended stocks >>
Blueprint Medicines (BPMC)
In a report released today, Marc Frahm from Cowen & Co. reiterated a Buy rating on Blueprint Medicines. The company’s shares opened today at $76.50.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 2.4% and a 57.6% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Unum Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $112 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
